Table 2

Sensitivity to PIM pharmacologic inhibition in a panel of DLBCL cell lines

LineIC50,* μM ETP-39010
DOHH-2 2.09 
OCILY-19 3.56 
SUDHL-6 0.66 
HBL-1 1.8 
OCILY-10 1.9 
OCILY-3 1.61 
RIVA 1.6 
U2932 4.9 
LineIC50,* μM ETP-39010
DOHH-2 2.09 
OCILY-19 3.56 
SUDHL-6 0.66 
HBL-1 1.8 
OCILY-10 1.9 
OCILY-3 1.61 
RIVA 1.6 
U2932 4.9 
*

The IC50 value was calculated for each of the DLBCL human cell lines. DLBCL cell lines were treated with 0 to 100μM ETP-39010 for 72 hours and then assayed for cell viability by MTT assay.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal